Differential influence of pentoxifylline on murine colon adenocarcinoma- and melanoma-derived metastatic tumor development in lungs

Oncology Reports

Volumn 11, Issue 5, 2004, Pages 1121-1125

  Lazarczyk, Maciej ^a   Grzela, Tomasz ^a,b   Niderla, Justyna ^a   Lazarczyk, Marta Alicja ^a   Milewski, Lukasz ^a   Dziunycz, Piotr ^a   Skopinski, Piotr ^a,b   Golab, Jakub ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Cancer; Colon adenocarcinoma; Lung; Melanoma; Metastasis; Pentoxifylline; Tumor

Indexed keywords

PENTOXIFYLLINE;

ADENOCARCINOMA; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; COLON TUMOR; DRUG SCREENING; LUNG TUMOR; MELANOMA; METASTASIS; MOUSE; PATHOLOGY;

ADENOCARCINOMA; ANIMALS; COLONIC NEOPLASMS; LUNG NEOPLASMS; MELANOMA; MICE; MICE, INBRED BALB C; PENTOXIFYLLINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 16544377563     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.11.5.1121     Document Type: Article

References (42)

1. Yamac K, Kaptan KM, Beyan C, Teksin ZS, Agabeyoglu IT and Gokgoz L: Comparison of the hematological effects of a sustained release chitosan formulation of pentoxifylline with a commercial formulation. Arzneimittelforschung 50: 827-831, 2000.
2. Nenci GG, Gresele P, Agnelli G and Ballatori E: Effect of pentoxifylline on platelet aggregation. Pharmatherapeutica 2: 532-538, 1981. (Pubitemid 11143946)
3. Ohshima N and Sato M: Effect of pentoxifylline on microvascular blood flow velocity. Angiology 32: 752-763, 1981. (Pubitemid 12173650)
4. Johnsson R: Effect of pentoxifylline on red cell flexibility and cation transport in healthy subjects and patients with hereditary spherocytosis. Scand J Haematol 23: 81-87, 1979.
5. Mueller R: On the therapy of disturbances of blood fluidity. Angiology 1: 226-234, 1985.
6. Aviado DM and Porter JM: Pentoxifylline: a new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy 4: 297-307, 1984. (Pubitemid 15181910)
7. Lindgarde F, Jelnes R, Bjorkman H, Adielsson G, Kjellstrom T, Palmquist I and Stavenow L: Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Scandinavian Study Group. Circulation 80: 1549-1556, 1989. (Pubitemid 20031683)
8. Porter JM, Cutler BS, Lee BY, Reich T, Reichle FA, Scogin JT and Strandness DE: Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 104: 66-72, 1982. (Pubitemid 13114585)
9. Cesarone MR, Belcaro G, Nicolaides AN, Griffin M, De Sanctis MT, Incandela L, Geroulakos G, Ramaswami G, Cazaubon M, Barsotti A, Vasdekis S, Bavera P and Ippolito E: Treatment of severe intermittent claudication with pentoxifylline: a 40-week, controlled, randomized trial. Angiology 53 (Suppl 1): 1-5, 2002.
10. Li YX, Sun LQ, Weber-Johnston K, Paschoudn N and Coucke PA: Potentiation of cytotoxicity and radiosensitisation of (E)-2-deoxy-2′-(fluoromethylene) cytydine by pentoxifylline in vitro. Int J Cancer 80: 155-160, 1999.
11. Fingert HJ, Pu AT, Chen ZY, Googe PB, Alley MC and Pardee AB: In vivo and in vitro enhanced antitumor effects by pentoxifylline in human cancer cells treated with thiotepa. Cancer Res 48: 4375-4381, 1988.
12. Serafin AM, Binder AB and Bohm L: Chemosensitivity of prostatic tumour cell lines under conditions of G2 block abrogation. Urol Res 29: 221-227, 2001. (Pubitemid 32622238)
13. Kim SH, Khil MS, Ryu S and Kim JH: Enhancement of radiation response on human carcinoma cell lines in culture by pentoxifylline. Int J Radiat Oncol 25: 61-65, 1993. (Pubitemid 23029774)
14. Sibtain A, Hill S, Goodchild K, Shah N, Saunders M and Hoskin PJ: The modification of human tumour blood flow using pentoxifylline, nicotinamide and carbogen. Radiother Oncol 62: 69-76, 2002. (Pubitemid 34121951)
15. Mannel RS, Blessing JA and Boike G: Cisplatin and pentoxifylline in advanced or recurrent squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group. Gynecol Oncol 79: 64-66, 2000.
16. Shapiro CL, Dezube BJ, Tretyakov O, Wright J, Cap B, Henderson IC and Hayes DF: Dose escalation of N,N',N'-triethylenethiophosphoramide combined with pentoxifylline for advanced breast cancer. Clin Cancer Res 1: 791-796, 1995.
17. Kwon HC, Kim SK, Chung WK, Cho MJ, Kim JS, Kim JS, Moon SR, Park WY, Ahn S J, Oh YK, Yun HG and Na BS: Effect of pentoxifylline on radiation response of non-small cell lung cancer: a phase III randomized multicenter trial. Radiother Oncol 56: 175-179, 2000.
18. Stewart DJ, Cripps MC, Fingert H, Lamothe A, Laframboise G and Gerin-Lajoie J: Cisplatin, cytosine arabinoside, and pentoxifylline in the treatment of squamous cell carcinoma of the head and neck. Am J Clin Oncol 16: 123-126, 1993. (Pubitemid 23109719)
19. Dominguez-Jimenez C, Sancho D, Nieto M, Montoya MC, Barreiro O, Sanchez-Madrid F and Gonzalez-Amaro R: Effect of pentoxifylline on polarization and migration of human leukocytes. J Leukoc Biol 71: 588-596, 2002.
20. Van Furth AM, Verhard-Seijmonsbergen EM, van Furth R and Langermans JA: Effect of lisofylline and pentoxifylline on the bacterial-stimulated production of TNF-alpha, IL-1 beta IL-10 by human leucocytes. Immunology 91: 193-196, 1997. (Pubitemid 27261561)
21. Moller DR, Wysocka M, Greenlee BM, Ma X, Wahl L, Trinchieri G and Karp CL: Inhibition of human interleukin-12 production by pentoxifylline. Immunology 91: 197-203, 1997. (Pubitemid 27261562)
22. Thanhauser A, Reiling N, Bohle A, Toellner KM, Duchrow M, Sheel D, Schluter C, Ernst M, Flad HD and Ulmer AJ: Pentoxifylline: a potent inhibitor of IL-2 and IFN-gamma biosynthesis and BCG-induced cytotoxicity. Immunology 80: 151-156, 1993. (Pubitemid 23284204)
23. Lazarczyk M, Grzela T, Korczak-Kowalska G, Niderla J, Oldak M, Jozwiak J and Skopinski P: Pentoxifylline inhibits perforin-dependent natural cytotoxicity in vitro. Oncol Rep 9: 423-426, 2002.
24. Lazarczyk M, Grzela T, Niderla J, Golab J, Korczak-Kowalska G, Oldak M and Skopinski P: Pentoxifylline inhibits leukocyte infiltration and splenocyte cytotoxicity against murine colon adenocarcinoma. Oncol Rep 10: 839-843, 2003.
25. Vernimmen F, Verheye-Dua F, Du Toit H and Böhm L: Effect of pentoxifylline on radiation damage and tumor growth. Strahlenther Onkol 10: 595-601, 1994. (Pubitemid 24332318)
26. Grzela T, Lazarczyk M, Niderla J, Golab J, Lazarczyk MA and Skopinski P: Pentoxifylline promotes development of murine colon adenocarcinoma-derived metastatic tumors in liver. Oncol Rep 10: 1805-1809, 2003.
27. Okamoto T: Pentoxifylline inhibits anti-Fas antibody-induced hepatitis by affecting down-stream of CPP32-like activity in mice. Int J Mol Med 4: 601-603, 1999.
28. Grzela T, Lazarczyk M, Oldak M and Korczak-Kowalska G: Influence of culture medium pH on cytotoxicity of CD95L in vitro. Folia Histochem Cytobiol 39: 29-33, 2001. (Pubitemid 32117848)
29. Engelhardt M and Martens UM: The implication of telomerase activity and telomere stability for replicative aging and cellular immortality. Oncol Rep 5: 1043-1052, 1998. (Pubitemid 28372558)
30. Johnson FE, Harrison BR, McKirgan LW, Raju PI, Roy TK and Virgo KS: A phase II evaluation of pentoxifylline combined with radiation in the treatment of brain metastases. Int J Oncol 13: 801-805, 1998. (Pubitemid 28435358)
31. Theron T, Binder A, Verheye-Dua F and Bohm L: The role of G2-block abrogation, DNA doublestrand break repair and apoptosis in the radiosensitization of melanoma and squamous cell carcinoma cell lines by pentoxifylline. Int J Radiat Biol 76: 1197-1208, 2000.
32. Binder A and Böhm L: Influence of irradiation and pentoxifylline on histone H3 phosphorylation in human tumour cell lines. Cell Prolif 35: 37-47, 2002. (Pubitemid 34592060)
33. Binder A, Theron T, Donninger H, Parker M and Bohm L: Radiosensitization and DNA repair inhibition by pentoxifylline in NIH3T3 p53 transfectants. Int J Radiat Biol 78: 991-1000, 2002. (Pubitemid 35333033)
34. Theron T and Böhm L: Influence of the G2 cell cycle block abrogator pentoxifylline on the expression and subcellular location of cyclin B1 and p34cdc2 in HeLa cervical carcinoma cells. Cell Prolif 33: 39-50, 2000. (Pubitemid 30162622)
35. Theron T and Bohm L: Cyclin B1 expression in response to abrogation of the radiation-induced G2/M block in HeLa cells. Cell Prolif 31: 49-57, 1998. (Pubitemid 28409854)
36. Binder AB, Serafin AM and Bohm LJ: Abrogation of G(2)/Mphase block enhances the cytotoxicity of daunorubicin, melphalan and cisplatin in TP53 mutant human tumor cells. Radiat Res 154: 640-649, 2000.
37. Viladkar A, Juvekar A, Chitnis M and Advani S: Amelioration of doxorubicin resistance by pentoxifylline in human chronic myeloid leukemia cells in vitro. Sel Cancer Ther 7: 119-126, 1991.
38. Stewart DJ, Evans WK and Logan D: Addition of pentoxifylline plus nifedipine to chemotherapy in patients with cisplatin-resistant cancers of the lung and other sites. Am J Clin Oncol 17: 313-316, 1994. (Pubitemid 24240937)
39. Sneed RA, Stevenson AP and Stewart CC: Quantitation of the host cell infiltration kinetics of the nonimmunogenic colon 26 by multiparameter flow cytometry. J Leukoc Biol 46: 547-555, 1989. (Pubitemid 19275133)
40. Wilcox RA, Files DB, Zhu G, Johnson AJ, Tamada K, Chapoval AI, Strome SE, Pease LR and Chen L: Provision of antigen and CD 137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest 109: 651-659, 2002. (Pubitemid 34204844)
41. Gude RP, Ingle AD and Rao SG: Inhibition of lung homing of B16F10 by pentoxifylline, a microfilament depolymerizing agent. Cancer Lett 106: 171-176, 1996. (Pubitemid 26325466)
42. Nagy Z, Sipka R, Ocsovszki I, Balogh A and Mandi Y: Suppressive effect of pentoxifylline on natural killer cell activity; experimental and clinical studies. Naunyn Schmiedebergs Arch Pharmacol 359: 228-234, 1999. (Pubitemid 29142874)